$VMNT
Vemanti Group, Inc.

2023 Q2 Form 10-Q Financial Statement

#000147793223003538 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $41.90K $30.32K $37.60K
YoY Change 15.82% -19.36%
Cost Of Revenue $5.361K $5.531K $5.520K
YoY Change -19.41% 0.2%
Gross Profit $36.54K $24.79K $32.08K
YoY Change 23.75% -22.72%
Gross Profit Margin 87.21% 81.76% 85.32%
Selling, General & Admin $363.0K $372.3K $329.0K
YoY Change 23.56% 13.18%
% of Gross Profit 993.46% 1501.75% 1025.41%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $8.040K $0.00 $184.00
YoY Change 4131.58% -100.0% -0.54%
% of Gross Profit 22.0% 0.0% 0.57%
Operating Expenses $371.1K $380.3K $328.9K
YoY Change 26.29% 15.62%
Operating Profit -$334.5K -$355.5K -$296.9K
YoY Change 26.58% 19.76%
Interest Expense -$5.020K $0.00
YoY Change -38715.38%
% of Operating Profit
Other Income/Expense, Net $630.00 $478.00 $436.00
YoY Change 238.71% 9.63% -126.41%
Pretax Income -$338.9K -$355.1K -$296.4K
YoY Change 28.24% 19.78% 323.68%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$338.9K -$355.1K -$296.4K
YoY Change 28.24% 19.78% 323.68%
Net Earnings / Revenue -808.83% -1170.98% -788.39%
Basic Earnings Per Share $0.00 -$0.01 $0.00
Diluted Earnings Per Share $0.00 -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 71.17M shares 70.52M shares 70.95M shares
Diluted Shares Outstanding 70.47M shares 70.95M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $230.9K $198.2K $540.9K
YoY Change -47.02% -63.35%
Cash & Equivalents $230.9K $198.2K $534.8K
Short-Term Investments $6.110K
Other Short-Term Assets $57.72K $151.3K
YoY Change
Inventory
Prepaid Expenses $57.72K $151.3K
Receivables $16.18K $2.653K $1.410K
Other Receivables $0.00 $0.00 $25.14K
Total Short-Term Assets $304.8K $352.1K $567.4K
YoY Change -31.27% -37.94%
LONG-TERM ASSETS
Property, Plant & Equipment $450.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $296.4K
YoY Change
Total Long-Term Assets $289.4K $297.4K $296.9K
YoY Change -10.07% 0.19%
TOTAL ASSETS
Total Short-Term Assets $304.8K $352.1K $567.4K
Total Long-Term Assets $289.4K $297.4K $296.9K
Total Assets $594.2K $649.6K $864.3K
YoY Change -22.35% -24.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.05K $29.73K $10.18K
YoY Change -35.47% 191.91%
Accrued Expenses $90.09K $223.0K $279.8K
YoY Change -73.72% -20.32%
Deferred Revenue
YoY Change
Short-Term Debt $276.9K $125.0K $125.0K
YoY Change 121.48% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $384.4K $430.2K $415.0K
YoY Change -21.24% 3.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $384.4K $430.2K $415.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $384.4K $430.2K $415.0K
YoY Change -21.24% 3.67%
SHAREHOLDERS EQUITY
Retained Earnings -$5.016M -$4.677M -$3.581M
YoY Change 30.47% 30.63%
Common Stock $7.172K $7.051K $7.151K
YoY Change 0.03% -1.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $209.8K $219.4K $449.3K
YoY Change
Total Liabilities & Shareholders Equity $594.2K $649.6K $864.3K
YoY Change -22.35% -24.84%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$338.9K -$355.1K -$296.4K
YoY Change 28.24% 19.78% 323.68%
Depreciation, Depletion And Amortization $8.040K $0.00 $184.00
YoY Change 4131.58% -100.0% -0.54%
Cash From Operating Activities -$217.3K -$59.28K -$98.65K
YoY Change 107.33% -39.91% 56.9%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $337.5K
YoY Change 27.36%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 250.0K 0.000 $337.5K
YoY Change -100.0% 27.36%
NET CHANGE
Cash From Operating Activities -217.3K -$59.28K -$98.65K
Cash From Investing Activities $0.00
Cash From Financing Activities 250.0K 0.000 $337.5K
Net Change In Cash 32.66K -$59.28K $238.9K
YoY Change -133.01% -124.82% 24.32%
FREE CASH FLOW
Cash From Operating Activities -$217.3K -$59.28K -$98.65K
Capital Expenditures $0.00
Free Cash Flow -$98.65K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Assets
Assets
806177 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
191470 usd
CY2022Q4 us-gaap Liabilities
Liabilities
323982 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
4000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4322308 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
482195 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
806177 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
380334 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001605057
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
40000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
40000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
40000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70524209 shares
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
715012 usd
CY2022Q4 us-gaap Investments
Investments
0 usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-56266
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
VEMANTI GROUP, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5317552
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
7545 Irvine Center Dr.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Ste 200
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92618
CY2023Q1 dei City Area Code
CityAreaCode
949
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
559-7200
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71165503 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
198232 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
257512 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
889 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
242307 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
500708 usd
CY2022Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
305469 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
305469 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6262 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1250 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
51280 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 usd
CY2022Q4 us-gaap Due To Officers Or Stockholders Current
DueToOfficersOrStockholdersCurrent
125000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
323982 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
40000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70524209 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70351709 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7035 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4793468 usd
CY2022Q1 us-gaap Revenues
Revenues
37600 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
24791 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
372295 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
328950 usd
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
8039 usd
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
0 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
329135 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
185 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-355543 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-297056 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
478 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
621 usd
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
478 usd
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
621 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-355065 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-296435 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-355065 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-296435 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70466709 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70953905 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70466709 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70953905 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
482195 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
92227 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-355065 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
219357 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
71843 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
337500 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
336390 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-296435 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
449298 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-296435 usd
CY2023Q1 vmnt Amortization Expense
AmortizationExpense
8039 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
123710 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
188912 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1764 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3008 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
91057 usd
CY2022Q1 vmnt Amortization Expense
AmortizationExpense
0 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
23463 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5681 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
51280 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59280 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-98650 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
337500 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
337500 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-59280 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
238850 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
257512 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295937 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
198232 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
534787 usd
CY2023Q1 us-gaap Reclassifications
Reclassifications
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain amounts reported in the prior year condensed consolidated financial statements have been reclassified to conform to the current year’s presentation.</p>
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include, among others, allowances for doubtful accounts, valuation allowance for deferred income taxes and recoverability of other assets and intangible assets. Actual results could differ from those estimates. It is possible that accounting estimates and assumptions may be material to the Company due to the levels of subjectivity and judgment involved.</p>
CY2023Q1 vmnt Customer Concentration
CustomerConcentration
0.50 pure
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
40000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70524209 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70351709 shares
CY2023Q1 vmnt Stock Issued During Period Shares For Cash
StockIssuedDuringPeriodSharesForCash
172500 shares
CY2023Q1 vmnt Stock Issued During Period Value For Cash
StockIssuedDuringPeriodValueForCash
92227 usd
CY2022Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
25000 usd
CY2023Q1 us-gaap Investments
Investments
0 usd
CY2023Q1 vmnt Proprietary Informations
ProprietaryInformations
0 usd
CY2022 vmnt Proprietary Informations
ProprietaryInformations
321547 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
8039 usd
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
16078 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
297430 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
305469 usd
CY2023Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
vmnt-20230331_cal.xml Edgar Link unprocessable
0001477932-23-003538-index-headers.html Edgar Link pending
0001477932-23-003538-index.html Edgar Link pending
0001477932-23-003538.txt Edgar Link pending
0001477932-23-003538-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vmnt-20230331.xsd Edgar Link pending
vmnt_10q.htm Edgar Link pending
vmnt_ex1017.htm Edgar Link pending
vmnt_ex1018.htm Edgar Link pending
vmnt_ex311.htm Edgar Link pending
vmnt_ex312.htm Edgar Link pending
vmnt_ex321.htm Edgar Link pending
vmnt_ex322.htm Edgar Link pending
vmnt_ex42.htm Edgar Link pending
vmnt-20230331_def.xml Edgar Link unprocessable
vmnt-20230331_lab.xml Edgar Link unprocessable
vmnt-20230331_pre.xml Edgar Link unprocessable
vmnt_10q_htm.xml Edgar Link completed